Growth Strategy: Evidence-Based Reimbursement and Commercialization Strategies for Innovators and Investors

In today’s rigorous health care environment new products must present a high profit and value proposition to potential investors and acquirers. Along with this increased level of scrutiny, payers are reviewing comparative effectiveness data and more carefully examining economic data for reimbursements. In this session panelists will discuss:

• Medicare product coverage strategy
  
• Proper planning for product pricing
  
• Preparing comparative effectiveness data
  
• Working with payer expectations
  
• Data that should be in place for partnering or acquisition deals

Panelists:

• Judith A. Waltz, Partner, Foley & Lardner LLP


• Anita Chawla, Ph.D., Vice President, Analysis Group


• Antoun Nabhan, Director of Corporate Development, Onyx Pharmaceuticals